Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Brimonidine Tartrate; Brinzolamide; Maleic acid; Timolol

Criteria

Inclusion Criteria:

• Clinical diagnosis of either open-angle glaucoma or ocular hypertension in both eyes.

• Willing and able to attend all study-related visits and be housed overnight at clinical site for the study assessments.

• Must sign an Informed Consent form.

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Women of childbearing potential if pregnant, breastfeeding, or not using adequate birth control.

• Severe central visual field loss in either eye.

• Chronic, recurrent or severe inflammatory eye disease.

• Ocular trauma or ocular surgery within the past 6 months.

• Ocular infection or ocular inflammation within the past 3 months.

• Clinically significant or progressive retinal disease.

• Other ocular pathology, including severe dry eye, that may in the opinion of the investigator preclude the administration of study medication.

• Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study.

• Any medical condition that would preclude the safe administration of a topical beta-blocker.

• Cannot safely discontinue all glucocorticoids administered by any route.

• Other protocol-specified exclusion criteria may apply.